Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Photochemotherapy Induces Interferon Type III Expression via STING Pathway

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Human P2X7 receptor causes cycle arrest in RPMI-8226 myeloma cells to alter the interaction with osteoblasts and osteoclasts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Crosstalk of Hedgehog and mTORC1 Pathways

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Key Components of Human Myofibre Denervation and Neuromuscular Junction Stability are Modulated by Age and Exercise

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

T-cells have a natural ability to fight cancer cells in the tumour microenvironment. Due to thymic selection and tissue-driven immunomodulation, these cancer-fighting T-cells are generally low in number and exhausted. One way to overcome these issues is to genetically alter T-cells to improve their effectiveness. This process can involve introducing a receptor that has high affinity for a tumour antigen, with two promising candidates known as chimeric-antigen receptors (CARs), or T-cell receptors (TCRs) with high tumour specificity. This review focuses on the editing of immune cells to introduce such novel receptors to improve immune responses to cancer. These new receptors redirect T-cells innate killing abilities to the appropriate target on cancer cells. CARs are modified receptors that recognise whole proteins on the surface of cancer cells. They have been shown to be very effective in haematological malignancies but have limited documented efficacy in solid cancers. TCRs recognise internal antigens and therefore enable targeting of a much wider range of antigens. TCRs require major histocompatibility complex (MHC) restriction but novel TCRs may have broader antigen recognition. Moreover, there are multiple cell types which can be used as targets to improve the "off-the-shelf" capabilities of these genetic engineering methods.

OriginalsprogEngelsk
TidsskriftCells
Vol/bind9
Udgave nummer7
ISSN2073-4409
DOI
StatusUdgivet - 30 jun. 2020

ID: 61243851